Trial Profile
An open, non-randomized, parallel-group pharmokinetic and -dynamic, investigator-initiated study on effects of obeticholic acid (OCA) in bile of patients with primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) in comparison to healthy controls
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2020
Price :
$35
*
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Alcoholic hepatitis; Biliary atresia; Cholelithiasis; Non-alcoholic steatohepatitis; Obesity; Primary biliary cirrhosis; Primary sclerosing cholangitis; Reperfusion injury
- Focus Pharmacokinetics
- Acronyms OCABILE
- 11 Jul 2017 New trial record